



Double data and dubious conclusions, 
‘Houston do we have a problem?’
J. L. Epker* , A. J. Valkenburg and E. J. O. Kompanje
© 2021 The Author(s)
With interest, as well as with some degree of concern, we 
read the article of Laserna et  al. published in Intensive 
Care Medicine [1].
The subject outlined in this article is very important 
for adequate end-of-life care in the ICU and the efforts 
that have been made to write this review are significant. 
Nevertheless, we think that a methodological mistake has 
been made in this review and meta-analysis.
The authors include 13 original studies in their data-
set; however, 2 of these studies as presented in Table  1 
of their manuscript refer to congress abstracts [2, 3]. 
Abstracts are normally intended to report preliminary 
data. These abstracts were indeed only “work in progress”, 
submitted to be presented at the ESCIM meetings in Ber-
lin 2011 and Lisbon 2012, respectively. The progress over 
time can be directly derived from the growing number 
of patients: 75 in the first abstract, 139 patients in the 
second abstract, and finally 241 patients in the publica-
tion in the Journal of Pain and Symptom Management 
[2–4]. In other words, 135 (60 + 75) patients are unfor-
tunately duplicate, which makes the analysis potentially 
unreliable.
Another problem of the article is that it only focusses 
on pain and its treatment; however, the authors do men-
tion in this context dosages of benzodiazepines and 
propofol, which are sedatives, definitely not analgesics.
The reason that the studies included do mention seda-
tives, is that pain is only one of the symptoms we treat 
as part of end-of-life care in the ICU. Fear, anxiety, dis-
tress, and dyspnea are other severe problems to deal 
with. Especially for these above-mentioned problems, 
the use of sedatives is essential; however, they should 
not be mistaken for or categorized with analgesics as the 
authors seem to do.
The effects of sedatives and analgesics are commonly 
confused in clinical practice. We, therefore, took the lib-
erty of using this opportunity to present a concise over-
view of the main effects of some of the most commonly 
used drugs in these categories in Table  1.  When caring 
for a terminally ill ICU patient, the indication for treat-
ment must be clear; is it pain that requires address or 
anxiety? Or is sedation required, because pain or anxiety 
can no longer be effectively controlled? The intensivist 
should choose the medication based on this important 
information.
Lastly, the authors suggest that the dosages observed 
are "too high" in relation to those recommended in end-
of-life guidelines.
However, as far as we know, the recommended doses of 
opioids and sedatives in end-of-life situations in the ICU 
are not based on clinical studies.
The only studies that provide evidence regarding the 
doses used for comfort care in the ICU are specifically 
the studies described in this article.
We, therefore, suggest that the article by Laserna et al. 
be seen as a first, and welcome, step in the development 
of an evidence-based guideline for treatment of pain and 
discomfort relief in end-of-life situations in the ICU and 
ideally, an additional study should be conducted, focus-
ing on the use of sedatives and anxiolytics in this same 
context.
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Table 1 Main effects of analgesics and sedatives
Sedation Analgesia Analgosedation Anxiety reduction Other effect
Morphine −  + −  ± 
Fentanyl −  + −  ± 
Sufentanil −  + −  ± 
Remifentanil  +  +  +  ± 
S-Ketamine  +  +  + 
Clonidine  + −  ±  + Opioid enhancing
Dexmethomidine  + − −  + 
Propofol  + − −  ± 
Midazolam  + − −  + 
Lorazepam  + − −  + 
